In this free webinar, supported by Cell Signaling Technology (CST) and hosted by DDW, Dr. Nathanael Gray, Professor of Chemical and Systems Biology at the Stanford Cancer Institute, will discuss an emerging strategy for cancer therapeutic development – targeted protein degradation (TPD).
Challenges and Opportunities in Protein Degradation, took place on 21 October 2021 and is available on demand here.
This approach has many advantages, including the ability to aim at previously inaccessible cancer targets using small molecule degraders that hijack cellular degradation machinery and E3 ubiquitin ligases to break down specific cancer proteins.
Gray’s work combining techniques in synthetic chemistry, protein biochemistry, and cancer biology has had a broad impact on kinase inhibitor and degrader design. With a history of integrative and collaborative research, Dr. Gray developed structure-based approaches to design drugs that can circumvent kinase drug resistance.
Recent chemo-proteomic work as led to the identification of ~200 kinases that are suitable for small molecule degrader-driven knock-down. These results shed light on effective methods for evaluating targeted protein degradation and strategies to identify potential therapeutic compounds.
Key Learning Objectives:
- How advances in targeted protein degradation can harness a cell’s degradation machinery to break down key cancer proteins
- Discover proteomics methods that led to an open-access curated library of small molecule compounds that degrade protein kinases
- How to find valuable leads for the development of selective degraders of understudied cancer targets
